GlassScriptPhysician profile
Jose S Subauste
NPI 1194758292
$3,770.90
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $77.71 · 2021: $426 · 2022: $1,100 · 2023: $336 · 2024: $735 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $542.68 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $355.63 | 2019-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $349.99 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $349.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $332.46 | 2021-2025 | Rybelsus, Ozempic, Sogroya |
| Pfizer INC. | $197.15 | 2019-2024 | |
| Corcept Therapeutics | $142.20 | 2021-2025 | Korlym |
| Grt US Holding, INC. | $128.80 | 2022 | |
| Recordati_rare_diseases_inc. | $126.96 | 2024-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $114.62 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $113.83 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.87 | 2019-2022 | |
| Medtronic, INC. | $108.04 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $97.35 | 2019-2024 | |
| Insulet Corporation | $89.19 | 2019-2024 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.36 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $83.54 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $78.90 | 2022-2023 | |
| Becton, Dickinson and Company | $78.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.96 | 2019-2022 | |
| Abbvie INC. | $55.40 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $43.40 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $41.42 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $24.44 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $23.58 | 2025 | Imcivree |
| Alexion Pharmaceuticals, INC. | $19.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Subauste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.